Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
3 Elite Growth Companies With Significant Insider Ownership

In This Article:

In a week marked by volatility and competitive pressures in the technology sector, global markets have been influenced by strategic moves such as the ECB's rate cuts and the Fed's decision to hold steady. Despite these fluctuations, investors continue to seek growth companies with significant insider ownership, as this often indicates strong confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Duc Giang Chemicals Group (HOSE:DGC)

31.4%

25.7%

Seojin SystemLtd (KOSDAQ:A178320)

32.1%

39.9%

Archean Chemical Industries (NSEI:ACI)

22.9%

41.2%

SKS Technologies Group (ASX:SKS)

29.7%

24.8%

Laopu Gold (SEHK:6181)

36.4%

36.4%

Pricol (NSEI:PRICOLLTD)

25.4%

25.2%

Medley (TSE:4480)

34.1%

27.3%

Fine M-TecLTD (KOSDAQ:A441270)

17.2%

135%

HANA Micron (KOSDAQ:A067310)

18.3%

119.4%

Fulin Precision (SZSE:300432)

13.6%

71%

Click here to see the full list of 1476 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

CanSino Biologics

Simply Wall St Growth Rating: ★★★★★☆

Overview: CanSino Biologics Inc. is a company that develops, manufactures, and commercializes vaccines in the People's Republic of China with a market cap of HK$10.89 billion.

Operations: The company generates revenue from the research and development of vaccine products for human use, amounting to CN¥748.53 million.

Insider Ownership: 28.9%

Earnings Growth Forecast: 128.6% p.a.

CanSino Biologics is positioned as a growth company with high insider ownership, evidenced by substantial insider buying in recent months. The company's forecasted revenue growth of 30.3% annually surpasses market averages, driven by strategic advancements in its vaccine portfolio, including the exclusive Menhycia® and new drug approvals like MCV4 in Indonesia. Despite expected net losses for 2024, CanSino's focus on commercialization and international expansion supports its potential for long-term growth.

SEHK:6185 Ownership Breakdown as at Feb 2025
SEHK:6185 Ownership Breakdown as at Feb 2025

Shenzhen Megmeet Electrical

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shenzhen Megmeet Electrical Co., LTD is involved in the R&D, production, sales, and services of hardware, software, and system solutions for electrical automation in China with a market cap of CN¥34.09 billion.

Operations: The company's revenue segments include the development and provision of hardware, software, and system solutions focused on electrical automation within China.